Pyxis Oncology, Inc. (PYXS) stock
PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.58+0.00 (0.00%)
Close on Nov 13, 2026Market cap $131.79MP/E –Yield –
Pyxis Oncology ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Pyxis Oncology's ebitda for the twelve months ending Sep 30, 2026 was -$85.21M. For fiscal 2025 it was -$79.91M. The highest annual figure on record is -$12.43M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$79.91M | – |
| FY2024 | Dec 31, 2024 | -$86.48M | – |
| FY2023 | Dec 31, 2023 | -$80.27M | – |
| FY2022 | Dec 31, 2022 | -$122.77M | – |
| FY2021 | Dec 31, 2021 | -$69.07M | – |
| FY2020 | Dec 31, 2020 | -$12.43M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$20.22M | – |
| Q2 FY2026 | Jun 30, 2026 | -$25.69M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$22.93M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.22M | – |
| Q1 FY2025 | Mar 31, 2025 | -$22.36M | – |
| Q4 FY2024 | Dec 31, 2024 | -$39.52M | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.02M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.45M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.49M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.08M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.83M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.76M | – |
| Q4 FY2022 | Dec 31, 2022 | -$37.78M | – |
| Q3 FY2022 | Sep 30, 2022 | -$28.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$25.57M | – |
| Q1 FY2022 | Mar 31, 2022 | -$31.23M | – |
| Q4 FY2021 | Dec 31, 2021 | -$16.27M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.46M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.72M | – |
| Q1 FY2021 | Mar 31, 2021 | -$35.62M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.41M | – |
See a number that looks wrong?